Fair Value Measurements - Additional Information (Details)		1 Months Ended		6 Months Ended
	Jan. 14, 2022 USD ($)	Mar. 31, 2022 shares	Oct. 31, 2018 USD ($) shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares	Jun. 10, 2016 shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from the issuance of common stock, net of issuance costs			$ 1,000,000	$ 2,000,000	$ 0
Non-current portion of contingent consideration				$ 2,460,000		$ 1,891,716
Merger Agreement, Upon Receipt of Phase II Positive Data
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional milestone payments payable	$ 3,000,000
Merger Agreement, Upon Initiation of Phase III Trial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional milestone payments payable	5,000,000
CEO
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from the issuance of common stock, net of issuance costs	800,000		$ 300,000
Number of shares issued (in shares) | shares			603
Hepion Employees
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from the issuance of common stock, net of issuance costs	200,000
Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, fair value measurement input				0.075		0.070	0.065
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, fair value measurement input						1.14	19.60
Ciclofilin
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from the issuance of common stock, net of issuance costs	$ 2,000,000		$ 700,000
Number of shares issued (in shares) | shares		4,317	1,439
Issuance of common stock in conjunction with milestone payment			$ 55,398
Percentage of issued and outstanding common stock	7.50%		2.50%
Ciclofilin | Merger Agreement, Upon Positive Analysis of Phase IIb Trial
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional milestone payments payable	$ 1,000,000
Ciclofilin | Merger Agreement, Upon Acceptance By FDA of New Drug
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional milestone payments payable	5,000,000
Ciclofilin | Merger Agreement Upon Approval by FDA Of New Drug
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional milestone payments payable	$ 8,000,000